Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Alkermes plc (ALKS) vs Kiniksa Pharmaceuticals International, plc (KNSA)

Alkermes plc and Kiniksa Pharmaceuticals International, plc are both Drug Manufacturers Specialty & Generic companies. Alkermes plc is the larger, with a market value of $6.8B against $5.9B — 1.1× the size. Kiniksa Pharmaceuticals International, plc trades at the lower P/E: 70.2× against 101×. Kiniksa Pharmaceuticals International, plc grew revenue faster over the last twelve months: 58.9% against 10.8%. Kiniksa Pharmaceuticals International, plc has the higher net margin (9.59% vs 3.97%) and the higher return on invested capital (48.9% vs 2.76%). Across the 20 metrics below, Kiniksa Pharmaceuticals International, plc leads on 14 and Alkermes plc on 6.

Valuation

Metric ALKS KNSA Drug Manufacturers Specialty & Generic median
P/E 101.36 70.17 20.14
P/S 4.09 6.93 2.25
P/B 3.77 8.90 1.90
Price to free cash flow 30.64 31.84 16.54
EV/EBITDA 34.45 51.93 12.29
EV/Sales 4.60 6.30 2.56
Earnings yield 0.99% 1.43% (2.99%)
Free cash flow yield 3.26% 3.14% 0.00%

Profitability

Metric ALKS KNSA Drug Manufacturers Specialty & Generic median
Gross margin 84.56% 89.82% 53.94%
Operating margin 7.03% 11.92% 0.00%
Net margin 3.97% 9.59% 0.00%
Free cash flow margin 13.35% 21.74% 0.00%
Return on equity 3.85% 14.04% (0.40%)
Return on assets 1.99% 10.36% (3.32%)
Return on invested capital 2.76% 48.87% 0.00%

Growth

Metric ALKS KNSA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 10.79% 58.85% 10.01%
EPS growth (last fiscal year) (34.10%) 225.00% —
Revenue growth, 5-year CAGR 7.28% — 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALKS KNSA Drug Manufacturers Specialty & Generic median
Debt to equity 0.83 0.00 0.05
Current ratio 2.30 3.90 2.31
Net debt to EBITDA (4.69) (5.26) 0.85

Dividend

Metric ALKS KNSA Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric ALKS KNSA Drug Manufacturers Specialty & Generic median
Market cap 6.78b 5.90b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack